Jin, Hua
Zhang, Yu
Yu, Sijian
Du, Xin
Xu, Na
Shao, Ruoyang
Lin, Dongjun
Chen, Yanqiu
Xiao, Jie
Sun, Zhiqiang
Deng, Lan
Liang, Xinquan
Zhang, Hongyu
Guo, Ziwen
Dai, Min
Shi, Pengcheng
Huang, Fen
Fan, Zhiping
Yin, Zhao
Xuan, Li
Lin, Ren
Jiang, Xuejie
Yu, Guopan
Liu, Qifa
Clinical trials referenced in this document:
Documents that mention this clinical trial
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
https://doi.org/10.1186/s13045-023-01437-1
Funding for this research was provided by:
National Natural Science Foundation of China (No. 82170215, No. 82200241, No.82270178, No.81970161)
National Key Research and Development Projects (No. 2021YFC2500300-2021YFC2500302)
Special Project for Research and Development in Key areas of Guangdong Province (No.2019B020236004)
Article History
Received: 23 November 2022
Accepted: 8 April 2023
First Online: 29 April 2023
Declarations
:
: This study was conducted in compliance with Declaration of Helsinki principles. All procedures were approved by the ethics committee review board of each participating hospital.
: Not applicable.
: The authors declare that they have no competing interests.